argenx (NASDAQ:ARGX), (EURONEXT:ARGX) is a biotechnology company focused on developing antibody-based therapies for the treatment of severe autoimmune diseases and cancer. With a deep and diverse pipeline, argenx aims to disrupt conventional treatment approaches by discovering novel antibodies that have the potential to transform patient outcomes. The company's flagship project, efgartigimod, targets a range of autoimmune conditions, showcasing argenx's commitment to addressing unmet medical needs. Through strategic collaborations and rigorous scientific research, argenx continues to push the boundaries of medicine to improve the lives of patients around the world.